Non-coding RNA biosensors for early detection of brain cancer

IF 3.2 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta Pub Date : 2024-11-17 DOI:10.1016/j.cca.2024.120041

Yousof karami , Sajad Ehtiati , Hassan Ghasemi , Maedeh Rafiee , Maryam Zamani Sani , Seyed Edris Hosseini , Hossein Moradi Kazerouni , Ahmad Movahedpour , Saleh Aiiashi , Seyyed Hossein Khatami

引用次数: 0

Abstract

Brain cancer remains a formidable challenge with limited treatment options. Non-coding RNAs (ncRNAs) have emerged as promising biomarkers due to their dysregulation in tumorigenesis. This review explores the potential of biosensors for early detection of brain cancer by targeting ncRNAs. We discuss the classification and functions of ncRNAs, emphasizing their involvement in key cancer-related processes. Additionally, we delve into recent advancements in biosensor technology, focusing on their ability to accurately detect specific ncRNA biomarkers associated with brain cancer. Our findings underscore the potential of biosensors to revolutionize brain cancer diagnosis, enabling personalized medicine and improving patient outcomes. Future research should focus on refining biosensor technology and expanding their clinical application.

查看原文本刊更多论文

用于早期检测脑癌的非编码 RNA 生物传感器。

脑癌仍然是一项艰巨的挑战，治疗方案有限。由于非编码 RNA（ncRNA）在肿瘤发生过程中的失调，它们已成为有前景的生物标记物。本综述探讨了生物传感器通过靶向 ncRNA 早期检测脑癌的潜力。我们讨论了 ncRNA 的分类和功能，强调了它们在关键癌症相关过程中的参与。此外，我们还深入探讨了生物传感器技术的最新进展，重点关注它们准确检测与脑癌相关的特定 ncRNA 生物标记物的能力。我们的研究结果强调了生物传感器在彻底改变脑癌诊断、实现个性化医疗和改善患者预后方面的潜力。未来的研究应侧重于完善生物传感器技术并扩大其临床应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinica Chimica Acta 医学-医学实验技术

CiteScore

10.10

自引率

2.00%

发文量

1268

审稿时长

23 days

期刊介绍： The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells. The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.